As one of the cancer hospitals serving Los Angeles County, the UCLA Jonsson Comprehensive Center has to face the challenge of providing the most sophisticated—and most expensive—care to a largely underserved population.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
The phase III Takeda TOURMALINE-MM4 study met its primary endpoint of progression-free survival in multiple myeloma not treated with stem cell transplantation.
A phase II study (NCT03491683) of newly diagnosed glioblastoma multiforme combining Inovio's INO-5401 and INO-9012 in combination with Libtayo (cemiplimab) showed that 80% (16 of 20) of MGMT gene promoter methylated patients and 75% (24 of 32) of unmethylated patients were progression-free at six months measured from the time of their first dose (n = 52), substantially exceeding historical standard-of-care data.
NCI and AppliedVR have formed a collaboration to evaluate whether virtual reality can address the underlying anxiety often experienced by many patients with terminal cancer.
Thermo Fisher Scientific launched its Ion Torrent Genexus System, a fully-integrated next-generation sequencing platform featuring an automated specimen-to-report workflow that, according to the company, is able to deliver results one day.
Carolyn Hayes was named chief nursing officer at RWJBarnabas Health, Oncology Services and Rutgers Cancer Institute of New Jersey.
Elaine Fuchs received the 24th annual Herbert and Maxine Block Memorial Lectureship Award for Distinguished Achievement in Cancer.
The Association of Community Cancer Centers honored the recipients of 2019 ACCC Innovator Awards at the ACCC 36th National Oncology Conference, Oct. 30-Nov. 1 in Orlando.
Otis Webb Brawley received the University of Chicago's Professional Achievement Award. He and other recipients were honored at the Alumni Medal Presentation and Alumni Professional Achievement Awards Ceremony Nov. 8.
